|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rapid Communication |
1 U.L.B. Hôpital Universitaire Erasme, Brussels, Belgium
* To whom correspondence should be addressed. E-mail: dblockle{at}ulb.ac.be.
| Abstract |
|---|
Granulocyte-colony stimulating factor administered for autologous hematopoietic stem cells (HSC) isolation from blood may favour restenosis in patients implanted after acute myocardial infarction (AMI). We therefore tested the isolation of peripheral-blood CD34+ cells without mobilisation in six patients with AMI. After large-volume cytapheresis and positive CD34+ cells selection, 3.6 to 27.6 millions CD34+ cells were obtained. We performed intra-coronary implantation of these cells and recorded no restenosis or arrhythmia. We used PET to assess myocardial labelled-CD34+ cell homing, which accounted for 5.5% of injected cells one hour post-implantation. In conclusion, large amounts of CD34+ cells, in the range reported in previous studies, can be obtained from non-mobilized peripheral blood. PET with FDG cell labelling is an efficient imaging method for homing assessment.
This article has been cited by other articles:
![]() |
M Penicka, O Lang, P Widimsky, P Kobylka, T Kozak, T Vanek, J Dvorak, J Tintera, and J Bartunek One-day kinetics of myocardial engraftment after intracoronary injection of bone marrow mononuclear cells in patients with acute and chronic myocardial infarction Heart, July 1, 2007; 93(7): 837 - 841. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Goussetis, A. Manginas, M. Koutelou, I. Peristeri, M. Theodosaki, N. Kollaros, E. Leontiadis, A. Theodorakos, G. Paterakis, G. Karatasakis, et al. Intracoronary Infusion of CD133+ and CD133-CD34+ Selected Autologous Bone Marrow Progenitor Cells in Patients with Chronic Ischemic Cardiomyopathy: Cell Isolation, Adherence to the Infarcted Area, and Body Distribution Stem Cells, October 1, 2006; 24(10): 2279 - 2283. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Oettgen Cardiac Stem Cell Therapy: Need for Optimization of Efficacy and Safety Monitoring Circulation, July 25, 2006; 114(4): 353 - 358. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
